The increase in prevalence of cervical cancer, infectious diseases like Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are expected to drive the global vaccine adjuvants market.
Also, the increase support of government in research & development, high incidences of epidermic outbreaks as well as tactical development interchanges adopted by companies like acquisitions, agreements, and collaborations are accelerating the global vaccine adjuvants market growth. For instance, in 2017, USFDA (Food and Drug Administration) had approved Nerlynx a product of Puma Biotechnology Inc. for adjuvant treatment of breast cancer.
Furthermore, the increase in focus on the long-lasting effect of immunization against existing and emerging diseases will positively influence the market growth. The importance of adjuvant research for the development of these products has raised significantly owing to the inadequate immunogenicity of innovative vaccine antigens. Also, the rise in use of recombinant and synthetic vaccines is expected to support the market growth throughout the forecast period.
High toxicity of adjuvants on application, huge investment required for developing a new adjuvant and strict regulatory requirements are some restraining factors which are expected to hamper the global vaccine adjuvants market growth. For instance, according to the information published Scientific Reports Journal revealed the toxicity of aluminum adjuvants in clinically approved various human vaccinations, in 2016.
On the basis of type, the global vaccine adjuvants market is segmented into a Pathogen, Adjuvant Emulsion, Combination, Particulate, and Others. The particulate type is expected to hold the largest market share in vaccine adjuvants market. Due to the availability of a wide range of products and greater efficiency against the diseases.
Further, market is segmented into route of administration such as Oral, Intranasal, Intramuscular, Intradermal, and Others. The intramuscular segment accounted for the largest market share in due to better immune specificity. On other hand, the market is segmented into application such as Infectious Disease, Cancer, and Others.
Impact of COVID-19
The increase in COVID-19 outbreak is expected to drive the global vaccine adjuvants market. Due to the crisis, majority of healthcare, pharmaceutical as well as biotechnology organizations have concentrated on treatment, vaccines and medication against Novel coronavirus.
Most of the leading companies are focusing on finding a breakthrough vaccine against COVID-19. Furthermore, pharmaceutical companies are prioritizing R&D of COVID-19 elated diagnostics, treatments, and vaccines. All these factors are expected to contribute the global vaccine adjuvants market growth over the forecast period.
The Global Vaccine Adjuvants Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The North America region holds the dominant position in global vaccine adjuvants market in terms of revenue, due to high adoption of the innovative products and presence of major market players in this region especially in the United States. Further, favorable government support towards the growth of healthcare infrastructure is also contribute the growth of the vaccine adjuvants market in this region.
Moreover, the APAC was estimated to be the fastest growing market owing to the continuously improving healthcare facilities such as the availability of medicines, coupled with the increase in research & development funding to meet the huge unmet demands. This is expected to increase the market share over the forecast period.
Some of the key players are listed in this report such as Novavax, Inc., GlaxoSmithKline plc., Puma Biotechnology, SEPPIC Inc., Aphios, OZ Biosciences, Agenus,Inc., Hayashibara Co., Ltd., Invivogen, MPV Technologies, etc. These companies are adopting strategies like collaborations, mergers & acquisitions, and new product development. For instance, in July 2017, GSK had collaborated with Exscientia for the development of new drugs.
Key Questions Addressed by the Report
What Are the Key Opportunities in Global Vaccine Adjuvants Market?
What Will Be the Growth Rate from 2019 to 2027?
Which Segment/Region Will Have Highest Growth?
What Are the Factors That Will Impact/Drive the Market?
What is the Competitive Landscape in the Industry?
What is the Role of Key Players in the Value Chain?
What Are the Strategies Adopted by Key Players?
Hayashibara Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/hp2394
View source version on businesswire.com: https://www.businesswire.com/news/home/20210723005431/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900